Global Blood Therapeutics Dividends and Buybacks
Dividend criteria checks 0/6
Global Blood Therapeutics does not have a record of paying a dividend.
Key information
n/a
Dividend yield
-2.1%
Buyback Yield
| Total Shareholder Yield | -2.1% |
| Future Dividend Yield | 0% |
| Dividend Growth | n/a |
| Next dividend pay date | n/a |
| Ex dividend date | n/a |
| Dividend per share | n/a |
| Payout ratio | n/a |
Recent dividend and buyback updates
No updates
Recent updates
Global Blood Therapeutics expects to complete Pfizer deal in early October
Sep 30Global Blood Therapeutics: Pfizer Acquisition Signals Increasing M/A Deals
Sep 16Pfizer said to have had bidding war with Johnson & Johnson for Global Blood
Aug 24What Pfizer Is Getting Through The Acquisition Of Global Blood Therapeutics
Aug 08Global Blood Therapeutics to expand access to its sickle cell disease treatment in Brazil
Jul 14GBT begins phase 2/3 clinical trial of GBT601 to treat sickle cell disease
Jun 29Global Blood Therapeutics: Powerhouse Of The Future
Jun 21Global Blood Therapeutics (NASDAQ:GBT) Is Making Moderate Use Of Debt
Jun 07
Global Blood Therapeutics: Hitting A Growth Inflection
Apr 12Global Blood Therapeutics: Changing My Strategy After Recent Earnings
Mar 12Is Global Blood Therapeutics (NASDAQ:GBT) Using Too Much Debt?
Feb 24Global Blood Therapeutics: Revisiting A Stellar Grower
Dec 25IBI Research On Global Blood Therapeutics: Galvanized For Growth
Nov 30Despite Lacking Profits Global Blood Therapeutics (NASDAQ:GBT) Seems To Be On Top Of Its Debt
Nov 03Global Blood Therapeutics: It Might Be Time To Buy The Dip
Oct 24Global Blood Therapeutics: Attempting To Classify The Investment
Aug 07Global Blood Therapeutics (NASDAQ:GBT) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Jul 08Shareholders May Not Be So Generous With Global Blood Therapeutics, Inc.'s (NASDAQ:GBT) CEO Compensation And Here's Why
Jun 12Global Blood Therapeutics announces employment inducement grants
Jun 04Global Blood Therapeutics: Increasing Specialization In SCD
May 09Is Global Blood Therapeutics (NASDAQ:GBT) A Risky Investment?
Mar 18Breakeven On The Horizon For Global Blood Therapeutics, Inc. (NASDAQ:GBT)
Feb 20
Did Business Growth Power Global Blood Therapeutics' (NASDAQ:GBT) Share Price Gain of 152%?
Jan 25Have Insiders Been Buying Global Blood Therapeutics, Inc. (NASDAQ:GBT) Shares?
Dec 29Stability and Growth of Payments
Fetching dividends data
Stable Dividend: Insufficient data to determine if GBT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GBT's dividend payments have been increasing.
Dividend Yield vs Market
| Global Blood Therapeutics Dividend Yield vs Market |
|---|
| Segment | Dividend Yield |
|---|---|
| Company (GBT) | n/a |
| Market Bottom 25% (US) | 1.4% |
| Market Top 25% (US) | 4.2% |
| Industry Average (Biotechs) | 2.3% |
| Analyst forecast (GBT) (up to 3 years) | 0% |
Notable Dividend: Unable to evaluate GBT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GBT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate GBT's payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as GBT has not reported any payouts.